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Abstract
Background Acidosis-induced kidney injury is mediated by the intrarenal renin-angiotensin system, for which urinary renin 
is a potential marker. Therefore, we hypothesized that sodium bicarbonate supplementation reduces urinary renin excretion 
in patients with chronic kidney disease (CKD) and metabolic acidosis.
Methods Patients with CKD stage G4 and plasma bicarbonate 15–24 mmol/l were randomized to receive sodium bicar-
bonate (3 × 1000 mg/day, ~ 0.5 mEq/kg), sodium chloride (2 × 1,00 mg/day), or no treatment for 4 weeks (n = 15/arm). The 
effects on urinary renin excretion (primary outcome), other plasma and urine parameters of the renin-angiotensin system, 
endothelin-1, and proteinuria were analyzed.
Results Forty-five patients were included (62 ± 15 years, eGFR 21 ± 5 ml/min/1.73m2, plasma bicarbonate 21.7 ± 3.3 mmol/l). 
Sodium bicarbonate supplementation increased plasma bicarbonate (20.8 to 23.8 mmol/l) and reduced urinary ammonium 
excretion (15 to 8 mmol/day, both P < 0.05). Furthermore, a trend towards lower plasma aldosterone (291 to 204 ng/L, 
P = 0.07) and potassium (5.1 to 4.8 mmol/l, P = 0.06) was observed in patients receiving sodium bicarbonate. Sodium bicar-
bonate did not significantly change the urinary excretion of renin, angiotensinogen, aldosterone, endothelin-1, albumin, or 
α1-microglobulin. Sodium chloride supplementation reduced plasma renin (166 to 122 ng/L), and increased the urinary 
excretions of angiotensinogen, albumin, and α1-microglobulin (all P < 0.05).
Conclusions Despite correction of acidosis and reduction in urinary ammonium excretion, sodium bicarbonate supplemen-
tation did not improve urinary markers of the renin-angiotensin system, endothelin-1, or proteinuria. Possible explanations 
include bicarbonate dose, short treatment time, or the inability of urinary renin to reflect intrarenal renin-angiotensin system 
activity.
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Introduction
Metabolic acidosis is a common complication in patients 
with chronic kidney disease (CKD). The prevalence of 
metabolic acidosis (usually defined as a plasma bicarbo-
nate concentration < 22 mmol/l) increases with higher 
CKD stage and is 26% and 47% for CKD stages G4 and 
G5, respectively [1,2]. Metabolic acidosis in CKD is asso-
ciated with a more rapid progression of CKD [3–5]. A 
recent systematic review showed that metabolic acidosis is 
a modifiable risk factor for CKD progression as interven-
tions with oral alkali supplementation or an alkaline diet 
reduce this risk [6]. However, the mechanisms of acidosis-
induced kidney injury are incompletely understood.
Current understanding of how acidosis contributes to 
kidney injury suggests that acid retention triggers an adap-
tive response to increase ammoniagenesis [7]. This process 
is orchestrated by activation of the circulating and intra-
renal renin-angiotensin systems (RAS) and endothelin-1. 
However, in a chronic setting and at the single-nephron 
level, this adaptive response may become maladaptive 
with the RAS and endothelin-1 contributing to inflam-
mation and fibrosis [8]. For example, it has been shown 
that locally produced ammonium can activate the com-
plement system with subsequent tubulo-interstitial inflam-
mation and fibrosis [9]. In rats, induction of CKD with 
2/3rd nephrectomy causes acid retention and higher lev-
els of angiotensin II and aldosterone in the kidney; alkali 
treatment reverses these changes [10]. In clinical studies, 
alkali treatment reduced plasma and urinary aldosterone in 
patients with CKD stage G2 and G4 [11,12]. Similar find-
ings have been reported for plasma and urinary endothe-
lin-1 [10,13–16]. However, the activity of the intrarenal 
RAS is difficult to assess because it is questionable to what 
degree urinary RAS components truly reflect intrarenal 
RAS activity [17, 18].
Previous data suggest that the production of angiotensin 
II in the kidney depends on filtered (i.e., blood-derived) 
components of the RAS, including renin and angiotensino-
gen [19–21]. Accordingly, the modest alkali-induced low-
ering of urinary angiotensinogen in patients with CKD 
stage G3 could suggest reduced intrarenal angiotensin 
generation [22]. Alternatively, urinary angiotensinogen 
may simply follow the same urinary excretion pattern as 
albumin.23 Since this is not the case for urinary renin, 
[23, 24] this marker may be a more attractive parameter 
to assess intrarenal RAS activity. Accordingly, we hypoth-
esized that sodium bicarbonate supplementation reduces 
urinary renin excretion in patients with CKD and meta-
bolic acidosis. To address this, we performed an open-
label clinical trial in which patients were randomized to 
receive sodium bicarbonate or sodium chloride, or served 
as time-controls. In addition to the measurement of plasma 
and urinary RAS parameters, we also analyzed the effects 
on urinary endothelin-1, albumin, α1-microglobulin, and 
complement.
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Methods
Study design
We conducted an open-label randomized controlled trial at 4 
study sites in The Netherlands, including Erasmus Medical 
Center, Rotterdam, Amsterdam University Medical Centers. 
University Medical Center Groningen and Leiden University 
Medical Center. The study was approved by the Medical 
Ethics Committee of the Erasmus Medical Center (MEC-
2013–332). The trial was registered at clinicaltrials.gov with 
registration number NCT02896309. Patients were recruited 
from outpatient nephrology clinics between April 2014 and 
December 2018. All patients with CKD stage G4 (eGFR 
15–30 ml/min/1.73m2) and with plasma bicarbonate levels 
between 15.0 and 24.0 mmol/l were eligible for inclusion. 
Exclusion criteria were sodium bicarbonate use in the month 
preceding the study, heart failure New York Heart Associa-
tion class 3 or 4, liver cirrhosis with ascites and the inability 
to withdraw diuretics, systolic blood pressure > 140 mmHg 
despite the use of three different antihypertensive drugs, 
kidney transplantation, and use of calcineurin inhibitors. 
Patients were randomized for 4-week treatment with sodium 
bicarbonate (3 × 1000 mg/day, providing a sodium load of 
36 mmol per day), sodium chloride (2 × 1000 mg/day, pro-
viding a sodium load of 34 mmol per day) or no treatment 
(time control). Allocation to treatment was done by rand-
omization using sequentially numbered, opaque, sealed 
envelopes. Stratified randomization was used to ensure that 
a similar number of patients were allocated to each interven-
tion at the different study sites.
Measurements
At baseline and after 2 and 4 weeks, blood and 24-h urine 
samples were collected and office blood pressure was meas-
ured. Plasma and urine electrolytes, albumin, creatinine, and 
α1-microglobulin were measured at the Department of Clini-
cal Chemistry of the Erasmus Medical Center. Venous blood 
gas analysis was performed directly after sample collection 
on a blood gas analyzer (ABL90 Flex Plus, Radiometer, 
The Netherlands; RAPIDLab 1265, Siemens, Germany). 
Estimated glomerular filtration rate (eGFR) was calculated 
using the CKD-EPI equation [25]. Creatinine clearance was 
calculated based on plasma and urinary creatinine excre-
tion. Urinary ammonium was measured using the Berth-
elot-method, as described previously [26]. Plasma renin was 
measured using a radioimmunometric assay (Cisbio, Saclay, 
France). Urinary renin was measured using an in-house 
enzyme-kinetic assay that quantifies angiotensin I genera-
tion in the presence of excess sheep angiotensinogen [27]. 
In order to convert angiotensin I-generating activity to renin 
concentration, a conversion factor was used based on the fact 
that 1 ng Ang I/mL per hour corresponds to 2.6 pg renin/
mL. Urinary angiotensinogen was measured as the maxi-
mum quantity of Ang I that was generated during incubation 
with excess recombinant renin using the same in-house assay 
[27]. Plasma and urinary aldosterone were measured by radi-
oimmunoassay (Demeditec, Kiel, Germany). Endothelin-1 
was measured using a Quantikine enzyme-linked immuno-
sorbent assay (ELISA; R&D systems, Minneapolis, USA). 
Urine soluble terminal complement complex sC5b-9 was 
measured by ELISA as previously described [28]. All uri-
nary excretions were expressed as ratio with urine creatinine 
to correct for any incomplete collections, as reported previ-
ously [29].
Statistics
Data are presented as frequencies (percentages), 
mean ± standard deviation and median with 10th–90th 
percentile, as appropriate. The primary outcome was the 
change in urinary renin-to-creatinine ratio. A power calcu-
lation based on previous data indicated that a minimum of 
45 patients (15 per treatment arm) was required to show that 
sodium bicarbonate supplementation would reduce urinary 
renin excretion by 0.3 ng/L (α = 0.025, β = 0.8, standard error 
0.26) [23]. Secondary outcomes included the urinary-to-cre-
atinine ratios of angiotensinogen, endothelin-1, albumin and 
α1-microglobulin. An exploratory analysis was performed 
for the treatment effects on kidney function, blood pressure 
and plasma potassium. The omnibus K2 test was used to 
test for normality. Non-normally distributed data were log-
transformed for statistical analysis. Primary and secondary 
outcomes were analyzed using mixed linear models that 
included treatment and period (time) as fixed effects. In 
case a significant interaction between treatment and period 
was found, post-hoc tests were performed with correction 
for multiple comparisons according to Dunnett. Data were 
analyzed using SPSS Statistics (IBM, version 24.0). P < 0.05 
was considered statistically significant.
Results
Baseline characteristics
Forty-seven patients entered the study protocol, of whom 
two patients discontinued treatment due to adverse reactions 
to sodium chloride supplementation (1 patient with gastro-
intestinal symptoms, 1 patient with polydipsia). Forty-five 
patients completed the study protocol (15 patients/arm). All 
patients that finished the treatment period were included in 
the analysis of the primary and secondary outcomes. The 
average age was 62 ± 15 years, 78% were males, the average 
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eGFR was 21 ± 15 ml/min/1.73 m2, and the average plasma 
bicarbonate was 21.7 ± 3.3 mmol/l (Table 1).
Effects on acid–base status 
and the renin‑angiotensin system
Sodium bicarbonate supplementation increased plasma 
bicarbonate (with 3.0 ± 0.7 and 2.9 ± 0.8  mmol/L after 
2 and 4 weeks of treatment, respectively; P < 0.01 versus 
baseline) and lowered urinary ammonium excretion (with 
− 7.0 ± 1.5 mmol/day and − 3.6 ± 1.9 mmol/day, P < 0.05 
versus baseline, Fig. 1). No significant changes in plasma 
bicarbonate or urinary ammonium excretion occurred with 
sodium chloride supplementation and without treatment. 
Sodium chloride but not sodium bicarbonate supplemen-
tation significantly reduced plasma renin (with − 9.5 and 
− 7.9 ng/L, P < 0.05 versus baseline, Fig. 1). A trend towards 
a reduction in plasma aldosterone was observed with sodium 
bicarbonate supplementation after 4 weeks (− 99 ng/L, 
P = 0.07). No changes in the aldosterone-to-renin ratio were 
observed with either treatment (data not shown).
Primary and secondary outcomes
In all three treatment groups, no significant within-group 
differences were detected in the urinary renin-to-creatinine 
ratio after two or four weeks of treatment (Table 2). In 
addition, no between-group differences were found. Simi-
larly, sodium bicarbonate supplementation had no signifi-
cant effect on any of the secondary outcome parameters 
(Table 2). In the within-group comparison, sodium chloride 
supplementation increased urinary angiotensinogen, albu-
min, and α1-microglobulin excretion; no between-group 
differences were shown for these outcomes (Table 2). Five 
patients did not use RAS-inhibitors. Two of these patients 
received sodium bicarbonate and this reduced urinary aldos-
terone (65% and 39% reduction after 2 and 4 weeks), an 
effect that was not observed with the other interventions. No 
effects on the other outcome parameters was observed. In 
addition, no differences were observed in a sensitivity analy-
sis of the primary and secondary outcomes between patients 
with CKD stage G4a (eGFR 29–23 mL/min per 1.73 m2) 
and G4b (eGFR 22–16 mL/min per 1.73 m2). To determine 
whether correction of metabolic acidosis reduced the activ-
ity of the complement system, we also measured soluble 
terminal complement complex sC5b-9 in urine at the end of 
treatment. Urine sC5b-9 was undetectable in forty patients 
Table 1  Baseline characteristics
Cr creatinine, eGFR estimated glomerular filtration rate, NaCl sodium chloride, NaHCO3 sodium bicarbonate, RAS renin-angiotensin system
Total (n = 45) NaHCO3 (n = 15) NaCl (n = 15) Time control (n = 15) P-value
Demographics
Age, years 62 ± 15 61 ± 17 61 ± 14 64 ± 14 0.9
Males, n (%) 35 (78) 11 (73) 14 (93) 10 (67) 0.2
European descent, n (%) 39 (87) 13 (87) 14 (93) 12 (80) 0.6
Comorbidities
eGFR, mL/min/1.73m2 21 ± 5 21 ± 6 22 ± 3 20 ± 4 0.6
Systolic blood pressure, mmHg 137 ± 16 134 ± 10 126 ± 13 135 ± 22 0.3
Use of RAS-inhibitors, n (%) 39 (87) 13 (87) 12 (80) 14 (93) 0.6
Diabetes mellitus, n (%) 7 (16) 2 (13) 2 (13) 3 (20) 0.8
Laboratory data
Plasma bicarbonate, mmol/l 21.7 ± 3.3 20.8 ± 3.9 21.8 ± 2.9 22.4 ± 3.1 0.4
Plasma potassium, mmol/l 5.0 ± 0.6 5.1 ± 0.7 5.0 ± 0.6 4.9 ± 0.5 0.6
Plasma renin, ng/l 41.8 (20.3, 119.4) 31.0 (18.4, 64.0) 75.2 (22.1, 130.4) 41.8 (16.0, 126.1) 0.5
Plasma aldosterone, ng/l 301 (175, 449) 236 (188, 427) 349 (155, 604) 332 (169, 415) 0.5
Urine sodium, mmol/mmol Cr 10.4 (8.8, 12.3) 10.4 (10.1, 13.7) 10.6 (8.5, 11.3) 9.8 (7.8. 13.5) 0.2
Urine ammonium, mmol/mmol Cr 1.2 (1.0, 1.6) 1.1 (0.9, 1.6) 1.0 (0.9, 1.9) 1.4 (1.1, 1.6) 0.6
Urine renin, ng/mmol Cr 1.1 (0.7, 2.0) 0.7 (0.5, 1.5) 1.1 (0.7, 2.1) 1.4 (1.0, 2.1) 0.5
Urine aldosterone, ng/mmol Cr 352 (272, 492) 337 (267, 632) 335 (289, 443) 353 (269, 461) 0.8
Urine angiotensinogen, µg/mmol Cr 3.4 (0.9, 14.5) 2.0 (0.6, 26.8) 7.1 (1.5, 12.3) 2.0 (1.2, 12.6) 0.9
Urine endothelin-1, ng/mmol Cr 0.02 (0.01, 0.05) 0.02 (0.01, 0.13) 0.02 (0.01, 0.02) 0.02 (0.02, 0.05) 0.3
Urine albumin, mg/mmol Cr 30 (5, 102) 30 (7, 93) 39 (6, 87) 16 (4, 96) 0.8
Urine α1-microglobulin, mg/mmol Cr 3.6 (2.0, 5.3) 3.9 (1.9, 6.4) 2.8 (2.2, 4.0) 3.8 (1.9, 6.2) 0.5
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Fig. 1  Sodium bicarbonate increased plasma bicarbonate and uri-
nary sodium excretion and lowered urinary ammonium excretion, 
whereas sodium chloride treatment only increased urinary sodium 
excretion after 2 weeks of treatment. The horizontal black lines rep-
resent the median value; the lower and upper boundaries of the box 
represent the 25th and 75th percentiles; the whiskers represent the 
lowest and highest values. HCO3− bicarbonate, K+ potassium, Na+, 
sodium, NaCl sodium chloride, NH4+ ammonium, NaHCO3 sodium 
bicarbonate. *P < 0.05 for the within-group difference from baseline. 
†P = 0.07 for the within-group difference versus baseline; #P < 0.05 
for the difference versus control
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Table 2  Treatment effects on urinary renin-angiotensin, endothelin-1, and protein excretions
Statistically significant results are highlighted in bold
Cr creatinine, NaCl sodium chloride, NaHCO3 sodium bicarbonate
*P < 0.05 for the within-group difference versus baseline
† P = 0.06 for the within-group difference versus baseline
Measurement Treatment Baseline 2 weeks 4 weeks
Urine renin, ng/mmol Cr NaHCO3 0.7, 0.4–2.2 0.9, 0.3–3.3 0.9, 0.2–3.1
NaCl 1.1, 0.3–3.7 1.1, 0.1–4.3 1.2, 0.2–5.4
Time control 1.4, 0.5–2.8 1.6, 0.5–2.4 1.8, 0.3–3.1
Urine aldosterone, ng/mmol Cr NaHCO3 337, 171–1179 318, 125–513 356, 166–426
NaCl 335, 142–787 337, 126–627† 317, 156–779
Time control 353, 216–501 394, 142–676 293, 181–750
Urine angiotensinogen, µg/mmol Cr NaHCO3 2.0, 0.4–83.5 4.3, 0.4–84.7 4.3, 0.2–104.5
NaCl 7.1, 0.5–22.9 7.7, 0.4–30.9* 6.2, 0.4–39.0*
Time control 2.0, 0.8–61.5 2.9, 0.9–55.3 5.5, 0.8–78.5
Urine endothelin-1, ng/mmol Cr NaHCO3 0.02, 0.01–0.56 0.05, 0.01–0.31 0.02, 0.01–0.29
NaCl 0.02, 0.01–0.07 0.02, 0.01–0.07 0.02, 0.01–0.07
Time control 0.02, 0.01–0.06 0.02, 0.01–0.04 0.02, 0.01–0.05
Urine albumin, mg/mmol Cr NaHCO3 30.4, 3.7–208.3 36.7, 5.8–196.9 40.4, 5.1–189.6
NaCl 38.7, 1.6–124.4 46.4, 1.2–130.3* 58.6, 1.4–177.1*
Time control 15.5, 1.9–171.2 17.6, 1.7–156.3 21.6, 2.1–160.7
Urine α1-microglobulin, mg/mmol Cr NaHCO3 3.9, 1.4–10.5 5.6, 1.1–11.1 5.2, 1.3–11.1
NaCl 2.8, 1.3–6.1 3.6, 1.3–8.0* 3.4, 1.4–8.1†
Time control 3.8, 1.0–9.3 6.2, 1.5–9.5 4.5, 1.0–10.8
Table 3  Effects of the sodium 
bicarbonate intervention on 
exploratory outcomes kidney 
function, blood pressure, and 
plasma potassium
Statistically significant results are highlighted in bold
eGFR estimated glomerular filtration rate, NaCl sodium chloride, NaHCO3 sodium bicarbonate
*P < 0.05 for the within-group difference from baseline
† P = 0.06 for the within-group difference from baseline
Measurement Treatment Baseline 2 weeks 4 weeks
eGFR, mL/min/1.73m2 NaHCO3 21 ± 6 21 ± 5 21 ± 5
NaCl 22 ± 3 22 ± 4 22 ± 4
Time control 20 ± 4 20 ± 4 20 ± 4
Creatinine clearance, mL/min NaHCO3 30 ± 10 29 ± 11 33 ± 12
NaCl 39 ± 12 39 ± 14 39 ± 14
Time control 32 ± 10 33 ± 10 30 ± 8
Creatinine excretion, mmol/day NaHCO3 10.7, 8.7–13.4 10.2, 8.0–11.9 11.1, 10.3–14.0*
NaCl 13.9, 10.9–17.0 12.5, 10.8–18.4 12.6, 10.7–16.6
Time control 10.3, 8.1–17.7 12.9, 7.4–15.2 10.7, 8.0–15.1
Systolic blood pressure, mmHg NaHCO3 134 ± 10 132 ± 18 132 ± 16
NaCl 126 ± 12 125 ± 13 123 ± 13
Time control 135 ± 22 140 ± 24 134 ± 20
Diastolic blood pressure, mmHg NaHCO3 76 ± 10 75 ± 10 75 ± 10
NaCl 78 ± 8 77 ± 9 78 ± 11
Time control 81 ± 12 81 ± 10 78 ± 12
Plasma potassium, mmol/l NaHCO3 5.1 ± 0.7 4.8 ± 0.5 4.8 ± 0.5†
NaCl 5.0 ± 0.6 4.9 ± 0.4 4.9 ± 0.4
Time control 4.9 ± 0.5 4.7 ± 0.4* 4.9 ± 0.5
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(< 0.05 U/ml). Of the five patients with detectable urinary 
complement, three had albuminuria > 1 g/day.
Effects on kidney function, blood pressure 
and plasma potassium
Sodium bicarbonate or sodium chloride supplementation did 
not lead to significant changes in eGFR (Table 3). However, 
sodium bicarbonate did cause a small but statistically signifi-
cant increase in urinary creatinine excretion after 4 weeks, 
which was not observed with sodium chloride treatment. 
No significant differences were identified for systolic and 
diastolic blood pressure within or between groups. After 
4 weeks, there was a trend towards a reduction in plasma 
potassium with sodium bicarbonate (P = 0.06 for difference 
baseline versus 4 weeks), which was not observed with 
sodium chloride and without treatment.
Discussion
In this open-label, three-arm randomized controlled trial 
(RCT) we investigated whether sodium bicarbonate sup-
plementation in patients with CKD and metabolic acidosis 
lowers urinary renin, as a potential measure of the intrarenal 
RAS. Sodium bicarbonate supplementation corrected meta-
bolic acidosis and lowered urinary ammonium excretion. 
Despite these effects, we observed no within- or between-
group differences for urinary renin. In addition, sodium 
bicarbonate had no significant effect on the urinary excre-
tion of angiotensinogen, aldosterone, endothelin-1, albumin, 
or α1-microglobulin. Despite these negative findings, we 
believe our study adds three relevant aspects to the evolving 
field of metabolic acidosis in CKD.
First, several other clinical trials with sodium bicarbo-
nate supplementation were also unable to show an effect on 
their primary endpoints. In this regard, our study is most 
comparable to the recent study by Raphael and colleagues 
who investigated the effect of sodium bicarbonate on uri-
nary kidney injury markers [29]. In their placebo-controlled, 
double-blind RCT sodium bicarbonate was supplemented 
for six months at a dose of 0.5 mEq/kg to patients with type 
1 or type 2 diabetes and an eGFR between 15 and 89 ml/
min/1.73m2. Sodium bicarbonate supplementation increased 
plasma bicarbonate and reduced urinary ammonium, but did 
not reduce urinary TGF-β1, KIM-1, fibronectin, NGAL, or 
albumin. The most likely explanation for a lack of effect is 
that the dose of sodium bicarbonate was too low. Indeed, 
most RCTs that were unable to show an effect on the primary 
endpoint used a dose of 0.3–0.5 mEq/kg [29−31], whereas 
positive RCTs used a higher dose of approximately 1.0 mEq/
kg [11,16,32]. To address this issue, Raphael et al. recently 
published a dose-finding study confirming that a higher dose 
of sodium bicarbonate (0.8 mEq/kg) had a stronger effect 
on plasma bicarbonate and urinary ammonium compared 
with a lower dose (0.5 mEq/kg). Wesson et al. showed that 
0.5 mEq/kg sodium bicarbonate supplementation for 30 days 
did reduce plasma aldosterone and endothelin-1 levels in 
patients with CKD stage G1 or G2.[12] In agreement, we 
also observed that sodium bicarbonate reduced plasma 
aldosterone, although this was of borderline significance. 
The effect of sodium bicarbonate on aldosterone may be 
mediated by lowering of plasma potassium, although this 
was also of borderline significance in our study. In the RCT 
by Melamed et al. sodium bicarbonate supplementation also 
increased plasma bicarbonate and reduced plasma potassium 
[30]. In contrast, three previous studies did find effects of a 
lower sodium bicarbonate dose (0.3 or 0.5 mEq/kg) on uri-
nary aldosterone, endothelin-1, angiotensinogen, albumin, 
and NAG, although the effect sizes were modest [12,15,16]. 
Possible explanations for the discrepancy with our study is 
that previous studies applied a longer treatment time (up 
to five years) and included patients with earlier stages of 
CKD. Finally, the use of RAS-inhibitors (used by 88% of 
the patients in this study) may suppress the RAS to an extent 
that alkali has no further effect.
A second issue that is raised by our study is whether uri-
nary renin can truly be considered a marker of the intrarenal 
RAS. Determinants of urinary renin excretion include glo-
merular filtration, proximal tubular reabsorption, local pro-
duction in the collecting duct, and intratubular conversion 
of plasma-derived prorenin to renin. In a study including 
101 patients with or without diabetes mellitus and hyperten-
sion, urinary renin did not correlate with plasma renin and 
especially dissociated in patients with diabetes mellitus or on 
RAS-inhibitors. Accordingly, we proposed urinary renin to 
be a marker for the intrarenal RAS [33,34]. In a subsequent 
study, however, we showed that the glomerular sieving coef-
ficient for renin is higher than for albumin and that varia-
tion in proximal tubular reabsorption explains the different 
urinary excretion patterns of renin and albumin [34]. We 
also showed that urinary renin does not reflect converted 
prorenin. A recent study in mice and humans with diabe-
tes confirmed these concepts and did not find evidence for 
local production of renin [35]. Together these recent insights 
suggest that urinary renin excretion is mainly determined 
by variation in glomerular filtration and proximal tubular 
reabsorption and is therefore not a good marker for the intra-
renal RAS. It would be of interest to explore whether renin 
mRNA or protein in urinary extracellular vesicles – which 
are mainly derived from tubular epithelial cells – is a bet-
ter read-out of intrarenal RAS [36]. This also implies that 
positive effects of oral alkali may have been obscured by 
counteracting effects of the sodium load on filtration or reab-
sorption. We recently showed that an acid load increases 
albuminuria [37]. Therefore, correction of acidosis would be 
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expected to reduce albuminuria, unless this effect is coun-
terbalanced, for example by the sodium load. This could 
also explain why fruits and vegetables have more positive 
effects than sodium bicarbonate [38]. In this regard it would 
be interesting to assess the effect of oral alkali given with 
another cation. A clinical trial that compares the effects of 
potassium citrate with potassium chloride and placebo on 
kidney outcomes in CKD stage G3b and G4 is currently 
ongoing and may provide more insight into this matter [39.]
A third relevant finding in our study is that sodium chlo-
ride but not sodium bicarbonate increased albuminuria. This 
is relevant, because the dose-finding study by Raphael et al. 
observed an increase in albuminuria with the high dose 
(i.e., 0.8 mEq/kg per day) but not with the low dose (i.e., 
0.5 mEq/kg per day) sodium bicarbonate [40]. The effect of 
alkali treatment on albuminuria is most likely the result of 
hemodynamic changes due to the sodium load given with 
bicarbonate. Another possibility is that a higher urine pH 
resulted in the detection of more intact albumin in the assay 
[41]. However, the results in our study and previous stud-
ies showing that sodium bicarbonate in both high and low 
doses also lowers albuminuria [11,15,22] suggest that assay 
characteristics do not fully explain the reported changes in 
albuminuria.
This is the first study to analyze the effect of sodium 
bicarbonate on urinary renin excretion. Another strength of 
this study is the inclusion of two control groups. However, 
this study also has a number of limitations. As discussed 
above, the dose of sodium bicarbonate or treatment time 
may explain why previously observed effects on aldoster-
one, endothelin-1, and proteinuria were not observed in this 
study. Although sample size was also modest, we recently 
showed in a study with a similar sample size that an acute 
acid load caused significant differences in urinary renin 
excretion between healthy subjects and patients with CKD 
[37]. Again, these results suggested that glomerular hyper-
filtration or reduced proximal tubular reabsorption caused 
these changes in urinary renin. Therefore, the lack of effect 
of sodium bicarbonate supplementation on urinary renin 
likely means that no net changes in filtration or reabsorp-
tion occurred.
In conclusion, despite correction of acidosis and reduc-
tion in urinary ammonium excretion, sodium bicarbonate 
supplementation did not improve urinary markers of the 
renin-angiotensin system, endothelin-1, or proteinuria. 
Explanations for the lack of effect include bicarbonate dose, 
treatment time, or the inability of urinary renin to reflect 
intrarenal renin-angiotensin system activity.
Acknowledgements We thank all patients who participated in this trial, 
our colleagues who helped with the inclusion of patients, the research 
physicians and nurses who helped with data collection (E.F.E. Wenst-
edt, M.A. De Jong, B.M. Voorzaat, B. Nome and N. Scheper-Van den 
Berg). This study was organized as part of the Dutch NOVO platform 
and was funded by a research grant from the Dutch Kidney Foundation 
(14OK19 to EJH).
Funding Dutch Kidney Foundation (14OK19 to EJH). 
Compliance with ethical standards  
Conflicts of interest No conflicts of interest to disclose.
Ethical approval This study was approved by the Medical Ethics Com-
mittee of the Erasmus Medical Center (MEC-2013-332).
Informed consent Informed consent was obtained from all participants.
Open Access This article is licensed under a Creative Commons Attri-
bution 4.0 International License, which permits use, sharing, adapta-
tion, distribution and reproduction in any medium or format, as long 
as you give appropriate credit to the original author(s) and the source, 
provide a link to the Creative Commons licence, and indicate if changes 
were made. The images or other third party material in this article are 
included in the article’s Creative Commons licence, unless indicated 
otherwise in a credit line to the material. If material is not included in 
the article’s Creative Commons licence and your intended use is not 
permitted by statutory regulation or exceeds the permitted use, you will 
need to obtain permission directly from the copyright holder. To view a 
copy of this licence, visit http://creat iveco mmons .org/licen ses/by/4.0/.
References
 1. Kim HJ, Kang E, Ryu H, Han M, Lee KB, Kim YS, Sung S, Ahn 
C, Oh KH (2019) Metabolic acidosis is associated with pulse wave 
velocity in chronic kidney disease: Results from the KNOW-CKD 
Study. Sci Rep 9:16139
 2. Moranne O, Froissart M, Rossert J, Gauci C, Boffa JJ, Haymann 
JP, M’Rad M B, Jacquot C, Houillier P, Stengel B, Fouqueray B 
and NephroTest Study G (2009) Timing of onset of CKD-related 
metabolic complications. J Am Soc Nephrol 20:164–171
 3. Madias NE. Metabolic Acidosis and CKD Progression. Clin J Am 
Soc Nephrol. 2020.
 4. Raphael KL, Carroll DJ, Murray J, Greene T, Beddhu S (2017) 
Urine Ammonium Predicts Clinical Outcomes in Hypertensive 
Kidney Disease. J Am Soc Nephrol 28:2483–2490
 5. Dobre M, Yang W, Chen J, Drawz P, Hamm LL, Horwitz E, 
Hostetter T, Jaar B, Lora CM, Nessel L, Ojo A, Scialla J, Steiger-
walt S, Teal V, Wolf M, Rahman M, Investigators C (2013) Asso-
ciation of serum bicarbonate with risk of renal and cardiovascular 
outcomes in CKD: a report from the Chronic Renal Insufficiency 
Cohort (CRIC) study. Am J Kidney Dis 62:670–678
 6. Navaneethan SD, Shao J, Buysse J, Bushinsky DA (2019) Effects 
of Treatment of Metabolic Acidosis in CKD: A Systematic 
Review and Meta-Analysis. Clin J Am Soc Nephrol 14:1011–1020
 7. Wesson DE, Buysse JM, Bushinsky DA (2020) Mechanisms of 
Metabolic Acidosis-Induced Kidney Injury in Chronic Kidney 
Disease. J Am Soc Nephrol 31:469–482
 8. Loniewski I, Wesson DE (2014) Bicarbonate therapy for preven-
tion of chronic kidney disease progression. Kidney Int 85:529–535
 9. Nath KA, Hostetter MK and Hostetter TH. Pathophysiology of 
chronic tubulo-interstitial disease in rats. Interactions of dietary 
acid load, ammonia, and complement component C3. J Clin 
Invest. 1985;76:667–75.
 10. Wesson DE, Simoni J (2010) Acid retention during kidney fail-
ure induces endothelin and aldosterone production which lead to 
Journal of Nephrology 
1 3
progressive GFR decline, a situation ameliorated by alkali diet. 
Kidney Int 78:1128–1135
 11. Goraya N, Simoni J, Jo CH, Wesson DE (2013) A comparison of 
treating metabolic acidosis in CKD stage 4 hypertensive kidney 
disease with fruits and vegetables or sodium bicarbonate. Clin J 
Am Soc Nephrol 8:371–381
 12. Wesson DE, Simoni J, Broglio K, Sheather S (2011) Acid reten-
tion accompanies reduced GFR in humans and increases plasma 
levels of endothelin and aldosterone. Am J Physiol Renal Physiol 
300:F830–F837
 13. Phisitkul S, Hacker C, Simoni J, Tran RM, Wesson DE (2008) 
Dietary protein causes a decline in the glomerular filtration rate of 
the remnant kidney mediated by metabolic acidosis and endothelin 
receptors. Kidney Int 73:192–199
 14. Wesson DE, Jo CH, Simoni J (2012) Angiotensin II receptors 
mediate increased distal nephron acidification caused by acid 
retention. Kidney Int 82:1184–1194
 15. Mahajan A, Simoni J, Sheather SJ, Broglio KR, Rajab MH, Wes-
son DE (2010) Daily oral sodium bicarbonate preserves glomer-
ular filtration rate by slowing its decline in early hypertensive 
nephropathy. Kidney Int 78:303–309
 16. Phisitkul S, Khanna A, Simoni J, Broglio K, Sheather S, Rajab 
MH, Wesson DE (2010) Amelioration of metabolic acidosis in 
patients with low GFR reduced kidney endothelin production and 
kidney injury, and better preserved GFR. Kidney Int 77:617–623
 17. Sun Y, Goes Martini A, Janssen MJ, Garrelds IM, Masereeuw R, 
Lu X, Danser AHJ (2020) Megalin: A Novel Endocytic Receptor 
for Prorenin and Renin. Hypertension 75:1242–1250
 18. Sun Y, Bovee DM, Danser AHJ (2019) Tubular (Pro)renin 
Release. Hypertension 74:26–28
 19. Gonzalez-Villalobos RA, Janjoulia T, Fletcher NK, Giani JF, 
Nguyen MT, Riquier-Brison AD, Seth DM, Fuchs S, Eladari D, 
Picard N, Bachmann S, Delpire E, Peti-Peterdi J, Navar LG, Bern-
stein KE, McDonough AA (2013) The absence of intrarenal ACE 
protects against hypertension. J Clin Invest 123:2011–2023
 20. van Kats JP, Schalekamp MA, Verdouw PD, Duncker DJ, Danser 
AH (2001) Intrarenal angiotensin II: interstitial and cellular levels 
and site of production. Kidney Int 60:2311–2317
 21. Seikaly MG, Arant BS Jr, Seney FD Jr (1990) Endogenous angio-
tensin concentrations in specific intrarenal fluid compartments of 
the rat. J Clin Invest 86:1352–1357
 22. Goraya N, Simoni J, Jo CH, Wesson DE (2014) Treatment of 
metabolic acidosis in patients with stage 3 chronic kidney dis-
ease with fruits and vegetables or oral bicarbonate reduces urine 
angiotensinogen and preserves glomerular filtration rate. Kidney 
Int 86:1031–1038
 23. van den Heuvel M, Batenburg WW, Jainandunsing S, Garrelds 
IM, van Gool JM, Feelders RA, van den Meiracker AH, Danser 
AH (2011) Urinary renin, but not angiotensinogen or aldosterone, 
reflects the renal renin-angiotensin-aldosterone system activity 
and the efficacy of renin-angiotensin-aldosterone system blockade 
in the kidney. J Hypertens 29:2147–2155
 24. Roksnoer LC, Verdonk K, van den Meiracker AH, Hoorn EJ, 
Zietse R, Danser AH (2013) Urinary markers of intrarenal renin-
angiotensin system activity in vivo. Curr Hypertens Rep 15:81–88
 25. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, 
Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh 
J, Ckd EPI (2009) A new equation to estimate glomerular filtration 
rate. Ann Intern Med 150:604–612
 26. Cunarro JA, Weiner MW (1974) A comparison of methods for 
measuring urinary ammonium. Kidney Int 5:303–305
 27. de Lannoy LM, Danser AH, van Kats JP, Schoemaker RG, Saxena 
PR, Schalekamp MA (1997) Renin-angiotensin system compo-
nents in the interstitial fluid of the isolated perfused rat heart. 
Local production of angiotensin I Hypertension 29:1240–1251
 28. Mollnes TE, Lea T, Froland SS, Harboe M (1985) Quantifica-
tion of the terminal complement complex in human plasma by an 
enzyme-linked immunosorbent assay based on monoclonal anti-
bodies against a neoantigen of the complex. Scand J Immunol 
22:197–202
 29. Raphael KL, Greene T, Wei G, Bullshoe T, Tuttle K, Cheung AK, 
Beddhu S (2020) Sodium Bicarbonate Supplementation and Uri-
nary TGF-beta1 in Nonacidotic Diabetic Kidney Disease: A Ran-
domized, Controlled Trial. Clin J Am Soc Nephrol 15:200–208
 30. Melamed ML, Horwitz EJ, Dobre MA, Abramowitz MK, Zhang 
L, Lo Y, Mitch WE, Hostetter TH (2020) Effects of Sodium Bicar-
bonate in CKD Stages 3 and 4: A Randomized, Placebo-Con-
trolled, Multicenter Clinical Trial. Am J Kidney Dis 75:225–234
 31. Csg Bi (2020) Clinical and cost-effectiveness of oral sodium bicar-
bonate therapy for older patients with chronic kidney disease and 
low-grade acidosis (BiCARB): a pragmatic randomised, double-
blind, placebo-controlled trial. BMC Med 18:91
 32. Di Iorio BR, Bellasi A, Raphael KL, Santoro D, Aucella F, Garo-
fano L, Ceccarelli M, Di Lullo L, Capolongo G, Di Iorio M, 
Guastaferro P, Capasso G and Group UBIS (2019) Treatment of 
metabolic acidosis with sodium bicarbonate delays progression of 
chronic kidney disease: the UBI Study. J Nephrol 32:989–1001
 33. Persson F, Lu X, Rossing P, Garrelds IM, Danser AH, Parving 
HH (2013) Urinary renin and angiotensinogen in type 2 diabetes: 
added value beyond urinary albumin? J Hypertens 31:1646–1652
 34. Roksnoer LC, Heijnen BF, Nakano D, Peti-Peterdi J, Walsh SB, 
Garrelds IM, van Gool JM, Zietse R, Struijker-Boudier HA, 
Hoorn EJ, Danser AH (2016) On the Origin of Urinary Renin: A 
Translational Approach. Hypertension 67:927–933
 35. Tang J, Wysocki J, Ye M, Valles PG, Rein J, Shirazi M, Bader M, 
Gomez RA, Sequeira-Lopez MS, Afkarian M, Batlle D (2019) 
Urinary Renin in Patients and Mice With Diabetic Kidney Dis-
ease. Hypertension 74:83–94
 36. Qi Y, Wang X, Rose KL, MacDonald WH, Zhang B, Schey KL, 
Luther JM (2016) Activation of the Endogenous Renin-Angioten-
sin-Aldosterone System or Aldosterone Administration Increases 
Urinary Exosomal Sodium Channel Excretion. J Am Soc Nephrol 
27:646–656
 37. Bovee DM, Janssen JW, Zietse R, AH JD and Hoorn EJ. Acute 
acid load in chronic kidney disease increases plasma potassium, 
plasma aldosterone and urinary renin. Nephrol Dial Transplant. 
2020;35:1821–1823.
 38. Goraya N, Munoz-Maldonado Y, Simoni J, Wesson DE (2019) 
Fruit and Vegetable Treatment of Chronic Kidney Disease-
Related Metabolic Acidosis Reduces Cardiovascular Risk Better 
than Sodium Bicarbonate. Am J Nephrol 49:438–448
 39. Gritter M, Vogt L, Yeung SMH, Wouda RD, Ramakers CRB, de 
Borst MH, Rotmans JI, Hoorn EJ (2018) Rationale and Design of 
a Randomized Placebo-Controlled Clinical Trial Assessing the 
Renoprotective Effects of Potassium Supplementation in Chronic 
Kidney Disease. Nephron 140:48–57
 40. Raphael KL, Isakova T, Ix JH, Raj DS, Wolf M, Fried LF, 
Gassman JJ, Kendrick C, Larive B, Flessner MF, Mendley SR, 
Hostetter TH, Block GA, Li P, Middleton JP, Sprague SM, Wes-
son DE, Cheung AK (2020) A Randomized Trial Comparing the 
Safety, Adherence, and Pharmacodynamics Profiles of Two Doses 
of Sodium Bicarbonate in CKD: the BASE Pilot Trial. J Am Soc 
Nephrol 31:161–174
 41. Kania K, Byrnes EA, Beilby JP, Webb SA, Strong KJ (2010) Uri-
nary proteases degrade albumin: implications for measurement of 
albuminuria in stored samples. Ann Clin Biochem 47:151–157
Publisher’s Note Springer Nature remains neutral with regard to 
jurisdictional claims in published maps and institutional affiliations.
